Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

Rhea-AI Summary

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the purchase of 100,000 common shares by Chief Medical Officer Matthew Davis at $0.76 per share. This move reflects confidence in the company’s future amidst its development of innovative immunotherapies using alternative drug delivery methods. Tiziana's flagship products, intranasal foralumab and milciclib, have shown promising safety profiles and clinical responses. The company focuses on transforming immunotherapy delivery to enhance efficacy and safety compared to traditional intravenous methods.

Positive

• Matthew Davis, Chief Medical Officer, purchased 100,000 shares, indicating insider confidence.
• Tiziana is developing innovative drug delivery methods for immunotherapies, which could enhance efficacy and safety.
• Lead candidates, intranasal foralumab and milciclib, have demonstrated favorable safety profiles and clinical responses.

Negative

• None.

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 100,000 common shares at $0.76 per share.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd

Hana Malik, Business Development, and Investor Relations Manager  
+44 (0) 207 495 2379
email: info@tizianalifesciences.com 

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com

FAQ

What recent insider transaction occurred at Tiziana Life Sciences (TLSA)?

Chief Medical Officer Matthew Davis purchased 100,000 shares at $0.76 each.

What are the key therapies being developed by Tiziana Life Sciences?

Tiziana Life Sciences is focused on intranasal foralumab and milciclib, utilizing novel drug delivery methods.

How does Tiziana Life Sciences plan to improve immunotherapy delivery?

The company is developing alternative delivery routes such as nasal, oral, and inhalation methods to enhance efficacy and safety.